FDA Approval Alert: The Need-to-Know | Epcoritamab in Relapsed/Refractory Follicular Lymphoma

In June 2024, the FDA granted accelerated approved epcoritamab-bysp as a treatment for patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of therapy.

The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Epcoritamab Approval in R/R Follicular Lymphoma May Offer Ease of Use
Video
Jul 9, 2024 12:00 PM
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.
Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma
Podcast
Jul 8, 2024 2:00 PM
Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.
Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma
Article
Jun 26, 2024 10:37 PM
Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.